Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Autorzy:
Schmitz A; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. Brøndum RF; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. Johnsen HE; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; For the Nordic Myeloma Study Group (NMSG). MellqvistUH; For the Nordic Myeloma Study Group (NMSG).; South Elvsborg Hospital, Boras, Sweden. Waage A; For the Nordic Myeloma Study Group (NMSG).; Norwegian University of Science and Technology and St. Olav's University Hospital, Trondheim, Norway. Gimsing P; For the Nordic Myeloma Study Group (NMSG).; Department of Haematology, University of Copenhagen, Copenhagen, Denmark. Op Bruinink DH; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. van der Velden V; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. van der Holt B; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.; HOVON Data Center, Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Hansson M; For the Nordic Myeloma Study Group (NMSG).; Skane University Hospital, Lund, Sweden. Andersen NF; For the Nordic Myeloma Study Group (NMSG).; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark. Frølund UC; For the Nordic Myeloma Study Group (NMSG).; Department of Haematology, Sjællands Universitetshospital, Roskilde, Denmark. Helleberg C; For the Nordic Myeloma Study Group (NMSG).; Department of Hematology, Herlev Hospital, Herlev, Denmark. Schjesvold FH; For the Nordic Myeloma Study Group (NMSG).; Oslo Myeloma Center, Department of Haematology, Oslo University Hospital, Olso, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. Ahlberg L; For the Nordic Myeloma Study Group (NMSG).; Division of Hematology, Linkoping University Hospital, Linkoping, Sweden. Gulbrandsen N; For the Nordic Myeloma Study Group (NMSG).; Oslo Myeloma Center, Department of Haematology, Oslo University Hospital, Olso, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. Andreasson B; For the Nordic Myeloma Study Group (NMSG).; NU Hospital Group, Uddevalla hospital, Uddevalla, Sweden. Lauri B; For the Nordic Myeloma Study Group (NMSG).; Sunderby Hospital, Luleaa, Sweden. Haukas E; For the Nordic Myeloma Study Group (NMSG).; Department of Haematology, Stavanger University Hospital, Stavanger, Norway. Bødker JS; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. Roug AS; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Bøgsted M; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Severinsen MT; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Gregersen H; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; For the Nordic Myeloma Study Group (NMSG). Abildgaard N; For the Nordic Myeloma Study Group (NMSG).; Department of Haematology, Odense University Hospital, Odense, Denmark. Sonneveld P; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.; For the European Myeloma Network (EMN). Dybkær K; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark. .; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. .; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Feb 05; Vol. 22 (1), pp. 147. Date of Electronic Publication: 2022 Feb 05.
Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.
Autorzy:
Baldursdóttir TR; Landspítali, National University Hospital, Reykjavík, Iceland. Löve ÞJ; Landspítali, National University Hospital, Reykjavík, Iceland.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland. Gíslason GK; Faculty of Medicine, University of Iceland, Reykjavik, Iceland. Björkholm M; Department of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden. MellqvistUH; Hematology, South Elvsborg Hospital, Boras, Sweden. Lund SH; Faculty of Medicine, University of Iceland, Reykjavik, Iceland. Blimark CH; Department of hematology, Sahlgrenska University Hospital, Gothenburg, Sweden. Turesson I; Skåne University Hospital, Malmö/Lund, Sweden. Hultcrantz M; Department of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.; Myeloma Service, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Landgren O; Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. Kristinsson SY; Landspítali, National University Hospital, Reykjavík, Iceland.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2021 Mar; Vol. 106 (3), pp. 380-388. Date of Electronic Publication: 2020 Dec 28.
Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry.
Autorzy:
Wålinder G; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Huddinge, Huddinge, Sweden. Samuelsson J; Department of Hematology, Linkoping University Hospital, Linköping, Sweden. Näsman P; Center for Safety Research, KTH Royal Institute of Technology, Stockholm, Sweden. Hansson M; Hematology, Lund University, Lund, Sweden.; Department of Hematology, Skåne University Hospital, Lund-Malmö, Sweden. Juliusson G; Hematology, Lund University, Lund, Sweden. Forsberg K; Department of Hematology, Norrlands University Hospital, Umeå, Sweden. Svensson R; Department of Hematology, Linkoping University Hospital, Linköping, Sweden. Linder O; Department of Hematology, Örebro University Hospital, Örebro, Sweden. Carlson K; Department of Hematology, Uppsala University Hospital, Uppsala, Sweden. Kristinsson SY; Department of Medicine, Karolinska Institutet, Stockholm, Sweden. MellqvistUH; Department of Hematology, South Elvsborg Hospital, Borås, Sweden. Hveding Blimark C; Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden. Turesson I; Hematology, Lund University, Lund, Sweden.; Department of Hematology, Skåne University Hospital, Lund-Malmö, Sweden. Nahi H; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.; Department of Hematology, Karolinska University Hospital Huddinge, Huddinge, Sweden.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2020 May; Vol. 104 (5), pp. 376-382. Date of Electronic Publication: 2020 Feb 22.
A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy.
Autorzy:
Weinfeld D; Asthma and Allergy Clinic Outpatient Unit (Adults), Department of Internal Medicine, South Alvsborgs Central Hospital, 50182 Boras, Sweden. Westin U; Division of Ear, Nose and Throat Diseases, Head and Neck Surgery, Department of Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden. Hellkvist L; 3Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden. MellqvistUH; Section of Hematology, Department of Internal Medicine, South Alvsborgs Central Hospital, Boras, Sweden. Jacobsson I; Clinical Chemistry, Department of Medical Imaging and Laboratory Medicine, South Alvsborgs Central Hospital, Boras, Sweden. Cardell LO; 3Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden.
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Autorzy:
Lund J; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden. Gruber A; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden. Lauri B; Department of Internal Medicine, Sunderby Hospital, Luleå, Sweden. Duru AD; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.; Nova Southeastern University (NSU), Fort Lauderdale, Florida. Blimark C; Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden. Swedin A; Department of Hematology, Skåne University Hospital, Lund, Sweden. Hansson M; Department of Hematology, Skåne University Hospital, Lund, Sweden. Forsberg K; Department of Hematology, Norrland University Hospital, Umeå, Sweden. Ahlberg L; Department of Hematology, University Hospital of Linköping, Linköping, Sweden. Carlsson C; Department of Internal Medicine, Hallands Hospital, Halmstad, Sweden. Waage A; Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. Gimsing P; Department of Hematology, Rigshospitalet, Copenhagen, Denmark. Vangsted AJ; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Department of Hematology, Zealand University, Roskilde, Denmark. Frølund U; Department of Hematology, Zealand University, Roskilde, Denmark. Holmberg E; Department of Oncology, Institute of Clinical Sciences, Gothenburg, Sweden. Gahrton G; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden. Alici E; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden. Hardling M; Department of Hematology, Uddevalla Hospital, Uddevalla, Sweden. MellqvistUH; Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden. Nahi H; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2018 Jun; Vol. 7 (6), pp. 2256-2268. Date of Electronic Publication: 2018 Apr 19.
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
Autorzy:
Gimsing P; Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Hjertner Ø; Department of Hematology, St. Olavs University Hospital, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Abildgaard N; Department of Hematology, Odense University Hospital, University of Southern Denmark, Odense, Denmark. Andersen NF; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark. Dahl TG; Department of Hematology, Rikshospitalet, Oslo, Norway. Gregersen H; Department of Hematology, Aalborg University Hospital, Denmark. Klausen TW; Department of Hematology, Herlev University Hospital, Herlev, Denmark. MellqvistUH; Department of Hematology, Sahlgrenska University Hospital, Gothenborg, Sweden. Linder O; Department of Hematology, Örebro University Hospital, Örebro, Sweden. Lindås R; Department of Hematology, Haukeland University Hospital, Bergen, Norway. Tøffner Clausen N; Department of Hematology, Herlev University Hospital, Herlev, Denmark. Lenhoff S; Department of Hematology, Skåne University Hospital, Lund, Sweden.
Pokaż więcej
Źródło:
Bone marrow transplantation [Bone Marrow Transplant] 2015 Oct; Vol. 50 (10), pp. 1306-11. Date of Electronic Publication: 2015 Jun 29.
Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis.
Autorzy:
Andersen JP; Medical Library, Aalborg University Hospital, Aalborg, Denmark. Bøgsted M; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Dybkær K; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. MellqvistUH; Department of Hematology Sahlgrenska Hospital, Gothenburg, Sweden; European Myeloma Network Board, Aalborg, Denmark. Morgan GJ; The Institute of Cancer Research Haematology & Oncology, London, United Kingdom; European Myeloma Network Board, Aalborg, Denmark. Goldschmidt H; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; European Myeloma Network Board, Aalborg, Denmark. Dimopoulos MA; Department of Clinical Therapeutics, University of Athens, Alexandra General Hospital, Athens, Greece; European Myeloma Network Board, Aalborg, Denmark. Einsele H; Department of Internal Medicine II, University of Würzburg, Würzburg, Germany; European Myeloma Network Board, Aalborg, Denmark. San Miguel J; Universidad de Navarra, Pamplona, Spain; European Myeloma Network Board, Aalborg, Denmark. Palumbo A; Department of Hematology, University of Turin, Turin, Italy; European Myeloma Network Board, Aalborg, Denmark. Sonneveld P; Erasmus University Hospital, Department of Hematology, Rotterdam, The Netherlands; European Myeloma Network Board, Aalborg, Denmark. Johnsen HE; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; European Myeloma Network Board, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Jan 28; Vol. 10 (1), pp. e0116966. Date of Electronic Publication: 2015 Jan 28 (Print Publication: 2015).
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
